ALVO — Alvotech
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1898416 ·
Last close
$4.37
Market Cap
$1.56B
52W High
$6.53
52W Low
$2.94
ADV30
1,002,984
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 111,398,000 | 59,579,000 | 12,810,000 | -74,868,000 | 1,616,043,000 | 61,468,000 | 1,883,310,000 |
| Jun 2026 | 105,772,000 | 53,575,000 | -11,705,000 | -66,821,000 | 1,587,468,000 | 142,750,000 | 1,778,947,000 |
| Mar 2026 | 105,865,000 | 59,778,000 | 9,674,000 | 1,030,000 | 1,421,168,000 | 63,832,000 | 1,703,480,000 |
| Dec 2025 | 166,573,000 | 105,293,000 | 48,255,000 | -108,547,000 | 1,487,099,000 | 172,359,000 | 1,771,586,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-198,702,000
Investing CF
$-146,183,000
Financing CF
$335,933,000
CapEx
$-135,122,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,475,581,000
Inventory
$226,551,000
Receivables
$132,381,000
ST Investments
—
EBIT TTM
$110,426,000
Pretax Income TTM
$-32,159,000
Interest Exp TTM
$142,585,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$494,608,000
EBITDA
$75,733,000
Free Cash Flow
$-123,130,128
Enterprise Value
$3,196,597,248
Total Cash
$142,750,000
Total Debt
$1,451,784,960
Shares Out
356,817,038
Trailing EPS
$-0.62
Book Value
$-0.54
ROE
—
ROA
2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 586,321,000 | 78,207,000 | 27,919,000 | 1,487,099,000 | 1,771,586,000 | -284,487,000 | -50,197,000 |
| Dec 2024 | 489,682,000 | 69,644,000 | -231,864,000 | 1,221,400,000 | 1,634,171,000 | -412,771,000 | -236,843,000 |
| Dec 2023 | 91,434,000 | -354,860,000 | -551,731,000 | 950,090,000 | 1,882,583,000 | -932,493,000 | -312,185,000 |
| Dec 2022 | 83,029,000 | -346,442,000 | -513,580,000 | 828,443,000 | 1,392,859,000 | -564,416,000 | -312,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MESO | MESOBLAST LTD | $1.55B | $11.91 | — |
| VIR | Vir Biotechnology, Inc. | $1.58B | $9.25 | — |
| LYCA | Lycia Therapeutics, Inc. | $1.61B | $30.92 | — |
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
News headlines (Yahoo Finance, 1h cache)
Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
2026-11-17 21:05 · Yahoo
Alvotech Stock After Earnings Loss What Changed
2026-11-15 08:12 · Yahoo
Alvotech (ALVO) Q3 2026 Earnings Call Transcript
2026-11-12 16:59 · Yahoo
What Alvotech (ALVO) Said on Its Q3 Earnings Call
2026-11-12 16:15 · Yahoo
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
2026-11-11 21:55 · Yahoo
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
2026-11-11 21:15 · Yahoo
Is Alvotech (NASDAQ:ALVO) Trading At A Discount To Its Sales?
2026-11-08 07:08 · Yahoo
Alvotech (ALVO) Dropped, What Is Driving Attention Now?
2026-11-08 01:15 · Yahoo
Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know
2026-11-04 14:00 · Yahoo
Alvotech to Present at Upcoming Investor Conferences in November
2026-11-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.